EGFR Cancer Research Results

EGFR, Epidermal Growth Factor Receptor: Click to Expand ⟱
Source: HalifaxProj(inhibit) CGL-Driver
Type: Oncogene
EGFR (Epidermal growth factor receptor), which belongs to the tyrosine kinase receptor family (RTKs)
Epidermal Growth Factor Receptor (EGFR) is a cell surface protein that plays a crucial role in the regulation of cell growth, survival, proliferation, and differentiation. It is part of the ErbB family of receptors and is activated by binding to its ligands, such as epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α).

-plays a crucial role in regulating cell growth and division.

Many cancers exhibit overexpression of EGFR, which can lead to enhanced signaling and contribute to tumor growth and survival. This overexpression is often associated with aggressive tumor behavior and poor prognosis.
NA, Not Available: Click to Expand ⟱
none (reserved)
Scientific Papers found: Click to Expand⟱
416- Api,    In Vitro and In Vivo Anti-tumoral Effects of the Flavonoid Apigenin in Malignant Mesothelioma
- vitro+vivo, NA, NA
Bax:Bcl2↑, P53↑, ROS↑, Casp9↑, Casp8↑, cl‑PARP1↑, p‑ERK⇅, p‑JNK↓, p‑p38↑, p‑Akt↓, cJun↓, NF-kB↓, EGFR↓, TumCCA↑,
556- ART/DHA,    Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing
- Review, NA, NA
IL6↓, IL1↓, TNF-α↓, TGF-β↓, NF-kB↓, MIP2↓, PGE2↓, NO↓, Hif1a↓, VEGFR2/KDR/Flk1↓, VEGF↓, MMP2↓, TIMP2↑, ITGB1↑, NCAM↑, p‑ATM↑, p‑ATR↑, p‑CHK1↑, p‑Chk2↑, Wnt/(β-catenin)↓, PI3K↓, Akt↓, ERK↓, cMyc↓, mTOR↓, survivin↓, cMET↓, EGFR↓, cycD1/CCND1↓, cycE1↓, CDK4/6↓, p16↑, p27/CDKN1B↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, oncosis↑, TumCCA↑, ROS↑, DNAdam↑, RAD51↓, HR↓,
2021- BBR,    Berberine: An Important Emphasis on Its Anticancer Effects through Modulation of Various Cell Signaling Pathways
- Review, NA, NA
*antiOx?, *Inflam↓, Apoptosis↑, TumCCA↑, BAX↑, eff↑, VEGF↓, PI3K↓, Akt↓, mTOR↓, Telomerase↓, β-catenin/ZEB1↓, Wnt↓, EGFR↓, AP-1↓, NF-kB↓, COX2↑, NRF2↓, RadioS↑, STAT3↓, ERK↓, AR↓, ROS↑, eff↑, selectivity↑, selectivity↑, BioAv↓, DNMT1↓, cMyc↓,
2745- BetA,    Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors
- in-vitro, CRC, RKO - in-vitro, CRC, SW480 - in-vivo, NA, NA
Apoptosis↑, TumCG↓, Sp1/3/4↓, survivin↓, VEGF↓, p65↓, EGFR↓, cycD1/CCND1↓, ROS↑, MMP↓,
643- EGCG,    New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate
- Analysis, NA, NA
H2O2↑, Fenton↑, PDGFR-BB↑, EGFR↓, VEGFR2/KDR/Flk1↓, IGFR↓, Ca+2↑, NO↑, Sp1/3/4↓, NF-kB↓, AP-1↓, STAT1↓, STAT3↓, FOXO↓, mtDam↑, TumAuto↑,
670- EGCG,    Epigallocatechin-3-gallate and its nanoformulation in cervical cancer therapy: the role of genes, MicroRNA and DNA methylation patterns
- Review, NA, NA
TumCCA↑, P53↑, ERK↓, EGFR↓, p‑ERK↑, VEGF↓, Hif1a↓, miR-203↓, miR-210↑,
682- EGCG,    Suppressive Effects of EGCG on Cervical Cancer
- Review, NA, NA
E7↓, E6↓, PI3K/Akt↓, P53↑, p27/CDKN1B↑, P21↑, CDK2↓, mTOR↓, HIF-1↓, IGF-1↓, EGFR↓, ERK↓, VEGF↓,
1232- Gra,    Graviola: A Systematic Review on Its Anticancer Properties
- Review, NA, NA
EGFR↓, cycD1/CCND1↓, Bcl-2↓, TumCCA↑, Apoptosis↑, ROS↑, MMP↓, BAX↑, Cyt‑c↑, Hif1a↓, NF-kB↓, GLUT1↓, GLUT4↓, HK2↓, LDHA↓, ATP↓,
834- Gra,    Anticancer Properties of Graviola (Annona muricata): A Comprehensive Mechanistic Review
- Review, NA, NA
EGFR↓, PI3K/Akt↓, NF-kB↓, JAK↓, STAT↓, Hif1a↓, GLUT1↓, GLUT4↓, ROS↑, Catalase↑, SOD↑, HO-1↑,
1153- HNK,    Honokiol Eliminates Glioma/Glioblastoma Stem Cell-Like Cells via JAK-STAT3 Signaling and Inhibits Tumor Progression by Targeting Epidermal Growth Factor Receptor
- in-vitro, GBM, U251 - in-vitro, GBM, U87MG - in-vivo, NA, NA
tumCV↓, Apoptosis↑, TumCMig↓, TumCI↓, Bcl-2↓, EGFR↓, CD133↓, Nestin↓, Akt↓, ERK↓, Casp3↑, p‑STAT3↓, TumCG↓,
7527- HT,    Hydroxytyrosol, a product from olive oil, reduces colon cancer growth by enhancing epidermal growth factor receptor degradation
- vitro+vivo, NA, HT29 - in-vitro, NA, Caco-2
EGFR↓, TumCP↓, TumCG↓,
518- MF,    Moderate and strong static magnetic fields directly affect EGFR kinase domain orientation to inhibit cancer cell proliferation
- in-vitro, NA, HCT116
EGFR↓, p‑EGFR↓,
1141- Myr,    Myricetin: targeting signaling networks in cancer and its implication in chemotherapy
- Review, NA, NA
*PI3K↑, *Akt↑, p‑Akt↓, SIRT3↑, p‑ERK↓, p38↓, VEGF↓, MEK↓, MKK4↓, MMP9↓, Raf↓, F-actin↓, MMP2↓, COX2↓, BMP2↓, cycD1/CCND1↓, Bax:Bcl2↑, EMT↓, EGFR↓, TumAuto↑,
1805- NarG,    Naringenin suppresses epithelial ovarian cancer by inhibiting proliferation and modulating gut microbiota
- in-vitro, Ovarian, A2780S - in-vivo, NA, NA
TumCP↓, TumCMig↓, PI3K↓, TumVol↓, TumW↓, BioAv↑, GutMicro↑, Dose∅, eff↑, EGFR↓, cycD1/CCND1↓, toxicity∅,
6492- Nimb,    Review on Molecular and Chemopreventive Potential of Nimbolide in Cancer
- Review, NA, NA
Apoptosis↑, TumCCA↑, TumCP↓, TumCI↓, angioG↓, TumMeta↓, PTEN↑, NF-kB↓, Wnt↓, β-catenin/ZEB1↓, IKKα↓, CXCR2↓, CXCR4↓, Bcl-2↓, COX2↓, MMP9↓, VEGF↓, TIMP2↑, chemoPv↑, ROS↑, DR4↑, P53↑, BAX↑, Casp3↑, Casp8↑, Casp9↑, cl‑PARP↑, Mcl-1↓, XIAP↓, survivin↓, FasL↑, FADD↑, EGFR↓, MMPs↓,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27/CDKN1B↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
3331- SIL,    The clinical anti-inflammatory effects and underlying mechanisms of silymarin
- Review, NA, NA
*Inflam↓, *NF-kB↓, *NLRP3↓, *COX2↓, *iNOS↓, *neuroP↑, *p‑ERK↓, *p38↓, *MAPK↓, *EGFR↓, *ROS↓, *lipid-P?, *5LO↓,
978- SIL,    A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment
- Review, NA, NA
PI3K↓, Akt↓, NF-kB↓, Wnt/(β-catenin)↓, MAPK↓, TumCP↓, TumCCA↑, Apoptosis↑, p‑EGFR↓, JAK2↓, STAT5↓, cycD1/CCND1↓, hTERT/TERT↓, AP-1↓, MMP9↓, miR-21↓, miR-155↓, Casp9↑, BID↑, ERK↓, Akt2↓, DNMT1↓, P53↑, survivin↓, Casp3↑, ROS↑,
2194- SK,    Efficacy of Shikonin against Esophageal Cancer Cells and its possible mechanisms in vitro and in vivo
- in-vitro, ESCC, Eca109 - in-vitro, ESCC, EC9706 - in-vivo, NA, NA
tumCV↓, TumCCA↑, Apoptosis↑, EGFR↓, PI3K↓, Hif1a↓, PKM2↓, cycD1/CCND1↓, AntiTum↑,
2414- β‐Ele,    Beta‐elemene inhibits breast cancer metastasis through blocking pyruvate kinase M2 dimerization and nuclear translocation
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7 - in-vivo, NA, NA
TumCMig↓, TumCI↓, TumMeta↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PKM2↓, EGFR↓, GLUT1↓, LDHA↓, ECAR↓, OCR↓,

Showing Research Papers: 1 to 20 of 20

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 20

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↑, 1,   Fenton↑, 1,   Ferroptosis↑, 1,   H2O2↑, 1,   HO-1↑, 1,   NRF2↓, 1,   ROS↓, 1,   ROS↑, 8,   SIRT3↑, 1,   SOD↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 2,   MEK↓, 1,   MKK4↓, 1,   MMP↓, 3,   mtDam↑, 1,   OCR↓, 1,   Raf↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

cMyc↓, 2,   ECAR↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 1,   HK2↓, 1,   lactateProd↓, 1,   LDHA↓, 2,   PI3K/Akt↓, 2,   PKM2↓, 2,   SIRT1↓, 1,   SREBP1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 4,   p‑Akt↓, 2,   Apoptosis↑, 8,   BAX↑, 3,   Bax:Bcl2↑, 2,   Bcl-2↓, 3,   BID↑, 1,   BMP2↓, 1,   Casp↑, 1,   Casp3↑, 3,   Casp8↑, 2,   Casp9↑, 3,   p‑Chk2↑, 1,   Cyt‑c↑, 2,   DR4↑, 1,   FADD↑, 1,   FasL↑, 1,   Ferroptosis↑, 1,   hTERT/TERT↓, 1,   p‑JNK↓, 1,   MAPK↓, 1,   Mcl-1↓, 1,   oncosis↑, 1,   p27/CDKN1B↑, 3,   p38↓, 1,   p‑p38↑, 1,   survivin↓, 4,   Telomerase↓, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

Sp1/3/4↓, 2,  

Transcription & Epigenetics(tgid=7) ⓘ

cJun↓, 1,   HATs↑, 1,   miR-21↓, 1,   tumCV↓, 2,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 3,  

DNA Damage & Repair(tgid=10) ⓘ

p‑ATM↑, 1,   p‑ATR↑, 1,   p‑CHK1↑, 1,   DNAdam↑, 1,   DNMT1↓, 2,   HR↓, 1,   p16↑, 1,   P53↑, 5,   cl‑PARP↑, 1,   cl‑PARP1↑, 1,   RAD51↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   CDK4↓, 1,   cycD1/CCND1↓, 7,   cycE1↓, 1,   P21↑, 2,   TumCCA↑, 9,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD133↓, 1,   CD44↓, 1,   cMET↓, 1,   EMT↓, 2,   ERK↓, 7,   p‑ERK↓, 1,   p‑ERK↑, 1,   p‑ERK⇅, 1,   FOXO↓, 1,   HDAC↓, 1,   IGF-1↓, 1,   IGFBP3↑, 1,   IGFR↓, 1,   mTOR↓, 3,   Nestin↓, 1,   NOTCH↓, 1,   PI3K↓, 5,   PTEN↑, 1,   STAT↓, 1,   STAT1↓, 1,   STAT3↓, 3,   p‑STAT3↓, 1,   STAT5↓, 1,   TumCG↓, 4,   Wnt↓, 3,   Wnt/(β-catenin)↓, 2,  

Migration(tgid=13) ⓘ

Akt2↓, 1,   AP-1↓, 3,   CA↓, 1,   Ca+2↑, 2,   CDK4/6↓, 1,   E-cadherin↑, 1,   F-actin↓, 1,   FAK↓, 1,   ITGB1↑, 1,   miR-155↓, 1,   miR-203↓, 1,   miR-203↑, 1,   MMP2↓, 3,   MMP9↓, 4,   MMPs↓, 1,   NCAM↑, 1,   PDGF↓, 1,   TGF-β↓, 2,   TIMP2↑, 2,   TumCI↓, 3,   TumCMig↓, 4,   TumCP↓, 4,   TumMeta↓, 2,   uPA↓, 1,   Vim↓, 1,   Zeb1↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   EGFR↓, 18,   p‑EGFR↓, 2,   HIF-1↓, 1,   Hif1a↓, 6,   miR-210↑, 1,   NO↓, 1,   NO↑, 1,   PDGFR-BB↑, 1,   VEGF↓, 9,   VEGFR2/KDR/Flk1↓, 2,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 3,   GLUT4↓, 2,   NHE1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 3,   COX2↑, 1,   CXCR2↓, 1,   CXCR4↓, 1,   IKKα↓, 1,   IL1↓, 2,   IL6↓, 1,   JAK↓, 1,   JAK2↓, 1,   MIP2↓, 1,   NF-kB↓, 9,   p65↓, 1,   PD-L1↓, 1,   PGE2↓, 2,   PSA↓, 1,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 4,   BioAv↑, 1,   Dose↝, 1,   Dose∅, 1,   eff↑, 3,   eff↝, 1,   Half-Life↓, 1,   Half-Life↝, 1,   RadioS↑, 1,   selectivity↑, 3,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 2,   E6↓, 1,   E7↓, 1,   EGFR↓, 18,   p‑EGFR↓, 2,   GutMicro↑, 1,   hTERT/TERT↓, 1,   IL6↓, 1,   PD-L1↓, 1,   PSA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   cardioP↑, 1,   chemoP↑, 1,   chemoPv↑, 1,   hepatoP↑, 1,   toxicity↝, 1,   toxicity∅, 2,   TumVol↓, 1,   TumW↓, 1,  
Total Targets: 194

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx?, 1,   antiOx↑, 1,   lipid-P?, 1,   ROS↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↑, 1,   iNOS↓, 1,   MAPK↓, 1,   p38↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

p‑ERK↓, 1,   PI3K↑, 1,  

Migration(tgid=13) ⓘ

5LO↓, 1,   TIMP1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

EGFR↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 1,   IL8↓, 1,   Inflam↓, 3,   NF-kB↓, 1,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,  

Functional Outcomes(tgid=23) ⓘ

neuroP↑, 1,  
Total Targets: 21

Scientific Paper Hit Count for: EGFR, Epidermal Growth Factor Receptor
3 EGCG (Epigallocatechin Gallate)
3 Silymarin (Milk Thistle) silibinin
2 Graviola
1 Apigenin (mainly Parsley)
1 Artemisinin
1 Berberine
1 Betulinic acid
1 Honokiol
1 HydroxyTyrosol
1 Magnetic Fields
1 Myricetin
1 Naringin
1 Nimbolide
1 Shikonin
1 β‐Elemene
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:0  Cells:%  prod#:%  Target#:94  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page